[Physiopathology of ALS: therapeutic approach]

Rev Neurol (Paris). 2004 Feb;160(2):235-41. doi: 10.1016/s0035-3787(04)70897-8.
[Article in French]

Abstract

The finding in 1993 of a mutation of the copper zinc super oxyde dismutase (SOD1) provides a major breakthrough in the understanding of the etiopathogenic mechanism of amyotrophic lateral sclerosis. Various mechanisms are commonly implied in the motor neurons degeneration. Excitotoxicity and calcium metabolism abnormalities are one of the most frequently confirmed hypotheses. It allowed proposing riluzole which remains the only one drug proved to be active in the disease. The role of growth factors remains controversial and all therapeutic trials performed with these molecules remained negative. Oxidative stress abnormalities are demonstrated by number of studies but their direct therapeutic application remains to be demonstrated. Apoptosis and the role of mitochondria has been definitely confirmed and open a new therapeutic avenue for the next few years.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Amyotrophic Lateral Sclerosis / genetics
  • Amyotrophic Lateral Sclerosis / metabolism
  • Amyotrophic Lateral Sclerosis / physiopathology*
  • Amyotrophic Lateral Sclerosis / therapy
  • Animals
  • Apoptosis
  • Axons / pathology
  • Calcium / metabolism
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Glutamic Acid / metabolism
  • Growth Substances / physiology
  • Growth Substances / therapeutic use
  • Humans
  • Intermediate Filaments / pathology
  • Mitochondria, Muscle / physiology
  • Motor Neurons / pathology
  • Oxidative Stress
  • Superoxide Dismutase / genetics

Substances

  • Growth Substances
  • Glutamic Acid
  • Superoxide Dismutase
  • Calcium